WICK- agreed on a couple things in your post, however, one RANCID difference- a developing company takes on huge debt and turns the corner once it produces enough to break even and then begins to whittle away at the debt...this company will not reach the time and place to begin whittling its debt for years while the nature of its debt ( the toxic interest formulae-conversion) continues to devalue the company. So it needs a dramatic infusion of capital to change that dampening dynamic.
I think ISC could thrive with 150M shares and NO debt but the problem is how to get a fair valuation for the price of new shares sold while the toxic diluter continues to dilute and hold the share price on the market at a very unfair valuation.
I doubt a sale in the answer. But to swing the infusion of needed capital, we need Superman to guide the deal. I expect a hybrid type deal. But think about this: I buy 50M shares at 1.15 and agree to not sell them for X years and we then begin integration of our products...in X years my 50M shares are worth 2.75 because we achieved our common goal while both companies sold plenty of product based on our integration...that's smart...now if buy the rest of ISC, the amt. I pay is worth it because I know the product inside out. Anyway, that's Superman's job now...
AI
